文献速递前列腺癌

保留Retzius间隙的机器人辅助根治性前列腺切除术与标准术式的系统评价及对比结局分析

Retzius-sparing robot-assisted radical prostatectomy vs the standard approach: a systematic review and analysis of comparative outcomes.
PubMed 文献 · BJU Int · 2019-08-26

该系统评价比较了保留Retzius间隙的机器人辅助根治性前列腺切除术(RS-RARP)与标准耻骨后RARP(S-RARP)的肿瘤学、围手术期和功能结局。结果显示RS-RARP手术时间更短(WMD 14.7分钟,95%CI -28.25至1.16;P=0.03),术后1、3、6、12个月控尿恢复均优于S-RARP,但S-RARP组切缘阳性率更低(15.2% vs 24%;OR 1.71,95%CI 1.12至2.60;P=0.01)。作者认为RS-RARP是安全可行的替代方案,但切缘阳性风险较高可能是当前的技术缺陷。

要点

  • RS-RARP手术时间较S-RARP缩短(WMD 14.7分钟,95%CI -28.25至1.16;P=0.03)。
  • RS-RARP在术后1、3、6、12个月控尿恢复方面均优于S-RARP。
  • S-RARP组切缘阳性率更低(15.2% vs 24%;OR 1.71,95%CI 1.12至2.60;P=0.01)。

核心结论

  • RS-RARP是S-RARP安全可行的替代方案,可能带来更快、更高的控尿恢复,且不增加并发症风险。
  • 切缘阳性风险较高可视为该技术当前的缺陷,可能与预期的学习曲线有关。

研究设计与样本

  • 系统评价与对比结局分析,遵循PICO标准和PRISMA指南,于2019年1月在Medline(通过PubMed)、Embase(通过Ovid)和Cochrane数据库进行系统电子文献检索。
  • 仅纳入报告RARP肿瘤学和功能结局并按术式(RS-RARP vs S-RARP)分组的研究,并评估偏倚风险和研究质量。

主要发现

  • RS-RARP与更短的手术时间相关(WMD 14.7分钟,95%CI -28.25至1.16;P=0.03),估计失血量无显著差异(WMD 1.45 mL,95%CI -31.18至34.08;P=0.93)。
  • 两组总体术后并发症(OR 0.86,95%CI 0.40至1.85;P=0.71)和主要并发症(Clavien >3;OR 0.88,95%CI 0.30至2.57)无显著差异。
  • S-RARP组切缘阳性率更低(率15.2% vs 24%;OR 1.71,95%CI 1.12至2.60;P=0.01)。
  • RS-RARP在术后1个月(OR 2.54,95%CI 1.16至5.53;P=0.02)、3个月(OR 3.86,95%CI 2.23至6.68;P<0.001)、6个月(OR 3.61,95%CI 1.88至6.91;P=0.001)和12个月(OR 7.29,95%CI 1.89至28.13;P=0.004)控尿恢复方面均显示统计学显著优势。

临床怎么用

  • 作者认为RS-RARP是S-RARP安全可行的替代方案,可能伴随更快、更高的控尿恢复,且不增加并发症风险。
  • 作者指出切缘阳性风险较高可视为该技术当前的缺陷,可能与预期的学习曲线有关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To summarize the current evidence on Retzius-sparing (RS)-robot-assisted radical prostatectomy (RARP) and to compare its oncological, peri-operative and functional outcomes with those of standard retropubic RARP (S-RARP). MATERIALS AND METHODS: After establishing an a priori protocol, a systematic electronic literature search was conducted in January 2019 using the Medline (via PubMed), Embase (via Ovid) and Cochrane databases. The search strategy relied on the 'PICO' (Patient Intervention Comparison Outcome) criteria and article selection was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Only studies reporting the oncological and functional outcomes of RARP (as determined by type of procedure [RS-RARP vs S-RARP]) were considered for inclusion. Risk of bias and study quality were assessed. Finally, peri-operative and functional outcomes were recorded and analysed. RESULTS: A shorter operating time was associated with RS-RARP (weighted mean difference [WMD] 14.7 min, 95% confidence interval [CI] -28.25, 1.16; P = 0.03), whereas no significant difference was found in terms of estimated blood loss (WMD 1.45 mL, 95% CI -31.18, 34.08; P = 0.93). Also, no significant difference between the two groups was observed for overall (odds ratio [OR] 0.86, 95% CI 0.40, 1.85; P = 0.71) and major (Clavien >3; OR 0.88, 95% CI 0.30, 2.57) postoperative complications; however, the likelihood of positive surgical margins (PSMs) was lower for the S-RARP group (rate 15.2% vs 24%; OR 1.71, 95% CI 1.12, 2.60; P = 0.01). The cumulative analysis showed a statistically significant advantage for RS-RARP in terms of continence recovery at 1 month (OR 2.54, 95% CI 1.16, 5.53; P = 0.02), as well as at 3 months (OR 3.86, 95% CI 2.23, 6.68; P < 0.001), 6 months (OR 3.61, 95% CI 1.88, 6.91; P = 0.001), and 12 months (OR 7.29, 95% CI 1.89, 28.13; P = 0.004). CONCLUSION: Our analysis confirms that RS-RARP is a safe and feasible alternative to S-RARP. This novel approach may be associated with faster and higher recovery of continence, without increasing the risk of complications. One caveat might be the higher risk of PSMs, and this can be regarded as a current pitfall of the technique, probably related to an expected learning curve.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Checcucci E, Veccia A, Fiori C, et al. Retzius-sparing robot-assisted radical prostatectomy vs the standard approach: a systematic review and analysis of comparative outcomes. BJU Int. 2019. PMID: 31373142. doi:10.1111/bju.14887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。